title: [Efficacy of colloid bismuth subcitrate (De-Nol) in gastropathies induced by nonsteroid anti-inflammatory drugs: an open controlled 4-week trial].
abstract: OBJECTIVE
  To evaluate efficiency of colloid bismuth subcitrate (CBS) in gastropathies induced by nonsteroid anti-inflammatory drugs (NSAID).
  
  
  METHODS
  45 patients with rheumatic diseases (RD) taking NSAID with gastric and/or duodenal up to 1 cm in size or multiple (more than 10) gastric mucosa erosions detected at esophagogastroduodenoscopy were randomized into two groups. Patients of group 1 (n = 30) received CBS (240 mg twice a day + amoxicillin 2 g/day and furozolidon 400 mg/day--subgroup 1a, n = 10 or CBS monotherapy in the same dose--subgroup 1b, n = 20). Patients of group 2 (n = 15) received ranitidine 150 mg twice a day. Older women, RA patients, patients with gastric ulcer prevailed. H. pylori was detected in 73.3 and 90% patients, respectively. Dispepsia and heartburn occurred in 90 and 93.3%, respectively. The efficacy was assessed after 4 weeks of therapy.
  
  
  RESULTS
  Healing of ulcers and erosions were achieved in 22 of 26 patients of group 1 (84.6%) and in 7 of 14 (50%) of group 2 (p = 0.036, chi-square). After therapy dyspepsia persisted in 4 patients of group 1 and 9 patients of group 2. Side effects were in 3 patients on CBS. Untiulcer effect did not differ between the subgroups (88.8 and 82.4%, respectively) and was effective in 6 of 7 HP-negative patients (85.7%) and in 8 of 10 HP-positive patients (80%).
  
  
  CONCLUSIONS
  De-Nol is effective in NSAID-induced gastropathies. Its action is not related with influence on HP.
authors.forename: A E
authors.initials: AE
authors.lastname: Karateev
authors.forename: E L
authors.initials: EL
authors.lastname: Nasonov
authors.forename: S G
authors.initials: SG
authors.lastname: Radenska-Lopovok
mesh_terms: D000368:Aged; D000891:Anti-Infective Agents, Local / Q000627:therapeutic use; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects; D000897:Anti-Ulcer Agents / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000453:epidemiology; D003967:Diarrhea / Q000139:chemically induced; D004334:Drug Administration Schedule; D004381:Duodenal Ulcer / Q000139:chemically induced / Q000175:diagnosis / Q000188:drug therapy*; D004384:Duodenoscopy; D004945:Esophagoscopy; D005260:Female; D005664:Furazolidone / Q000627:therapeutic use; D016481:Helicobacter Infections / Q000453:epidemiology; D016480:Helicobacter pylori; D006801:Humans; D008297:Male; D008875:Middle Aged; D009942:Organometallic Compounds / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D015995:Prevalence; D011899:Ranitidine / Q000627:therapeutic use; D012720:Severity of Illness Index; D017678:Sex Distribution; D013276:Stomach Ulcer / Q000139:chemically induced / Q000175:diagnosis / Q000188:drug therapy*
chemical_list: D000891:Anti-Infective Agents, Local; D000894:Anti-Inflammatory Agents, Non-Steroidal; D000897:Anti-Ulcer Agents; D009942:Organometallic Compounds; D005664:Furazolidone; D011899:Ranitidine; C002791:bismuth tripotassium dicitrate